CARDIOPROGRESS
Foundation for the advancement of cardiology

PARTNER 2A Intermediate-Risk TAVR Five-Year Results Hit Print Late outcomes of transcatheter aortic valve replacement (TAVR) in the PARTNER 2A trial are now enshrined in the peer-reviewed literature.

New report reveals the role of physical activity in preventing and treating cardiovascular diseases The European Heart Network, in collaboration with the WHO European Office for the Prevention and Control of Noncommunicable Diseases, has published an important report on physical activity policies for cardiovascular health. Each year, cardiovascular diseases cause 3.9 million deaths in Europe and over 1.8 million deaths in the European Union. Physical inactivity increases the risk of cardiovascular diseases by more than 20%.

A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement Whether the direct factor Xa inhibitor rivaroxaban can prevent thromboembolic events after transcatheter aortic-valve replacement (TAVR) is unclear.

Ticagrelor Sans Aspirin Trial Answers Some Questions About DAPT Hi. My name is Robert Byrne. I'm an interventional cardiologist at the German Heart Center in Munich and am here at TCT 2019 in San Francisco, where we've seen some interesting results from the TWILIGHT study. I would like to discuss some of the implications of this study for clinical practice.

From Naysayer to Convert: Cardiologists Should Prescribe SGLT2 Inhibitors Сardiologists have largely resisted calls to get more involved in diabetes. The comments on the Medscape article "Cardiologists Must Get Up to Speed on Treating Diabetes" echoed the sentiments of many regarding sodium-glucose contransporter-2 (SGLT2) prescribing.

MITRA-FR at 2 Years: MitraClip Still No Better Than Med Therapy Patrice Wendling PARIS — An additional year of follow-up in the MITRA-FR trial confirm no added benefit of percutaneous repair of functional mitral regurgitation (MR) with the MitraClip (Abbott) compared with optimal medical therapy alone.

Daily Aspirin May Lower Risk for Fatty Liver Progression Taking daily aspirin may prevent progression of nonalcoholic fatty liver disease (NAFLD) to liver fibrosis and nonalcoholic steatopepatitis (NASH), according to a study published online May 8 in Clinical Gastroenterology and Hepatology.

Novel Carotid Filter Aims for Stroke Prevention in Afib Stroke prophylaxis with a novel permanent filter implanted in the carotid arteries is feasible for high risk atrial fibrillation (Afib) patients, a pilot trial showed.

Excess Vitamin D Linked to Kidney Damage Vitamin D has been reported to have a wide range of benefits. However, a recent case study indicates that excessive use of vitamin D can cause kidney damage in people who are not deficient in the vitamin.

Dad's Smoking Tied to Baby's Heart Defect Risk Results from a large meta-analysis indicate that paternal smoking during a mother's pregnancy is a significant and independent risk factor for congenital heart defects (CHD) among offspring, as is secondhand smoke exposure in general. Meta-analysis suggests smoke exposure from any source is problematic during pregnancy.

Redefining CVD Risk: Cardiovascular-Kidney-Metabolic (CKM) Syndrome Citing the strong overlap between heart disease, kidney disease, type 2 diabetes, and obesity, the American Heart Association (AHA) has for the first time formally defined what they are calling cardiovascular-kidney-metabolic (CKM) syndrome.

ACP Revises Standard on Cardiorespiratory Death Determination The American College of Physicians (ACP) has issued a new position paper on determination of death that includes a clarification to the 1981 Uniform Determination of Death Act (UDDA), but otherwise reaffirms the current standards.

FDA Clears Architect Stat High-Sensitivity Troponin Test for MI The US Food and Drug Administration (FDA) has approved the Architect Stat (Abbott Laboratories) high-sensitivity troponin-I assay, which can detect myocardial infarction (MI) faster and more accurately than other troponin tests, according to the company.

World Heart Day 2019 This year on World Heart Day, as part of our mission to ensure heart health equity for all, we want to create a global community of Heart Heroes … people from all walks of life who are acting now to live longer, better, heart-healthy lives by making a promise: for MY HEART, for YOUR HEART, for ALL OUR HEARTS.

ESC 2019: Wrap up in Russian - Live and interactive programme In collaboration with the Russian Society of Cardiology, this programme is designed to present a selection of scientific highlights from ESC Congress and discuss clinical practice implications with experts.

ESC Congress 2019 together with World Congress of Cardiology ESC Congress 2019 together with World Congress of Cardiology Saturday 31 August - Wednesday 4 September 2019 Paris - France

Announcement of the European Congress of Cardiology From August 31 to September 4, 2019, he Congress of the European Society of Cardiology in conjunction with the World Congress of Cardiology - will be held in Paris (France).

Trial Evaluating Sacubitril/Valsartan for HFpEF Misses Primary End Point Full detailed data from PARAGON-HF will be presented at the ESC Congress 2019 in September. Novartis announced topline results from the phase 3 PARAGON-HF study evaluating the safety and efficacy of sacubitril/valsartan (Entresto) in heart failure patients with preserved ejection fraction (HFpEF).

ESC Congress 2019 together with World Congress of Cardiology Full detailed data from PARAGON-HF will be presented at the ESC Congress 2019 in September. Novartis announced topline results from the phase 3 PARAGON-HF study evaluating the safety and efficacy of sacubitril/valsartan (Entresto) in heart failure patients with preserved ejection fraction (HFpEF).

Certain Social, Behavioral Factors Associated With Diabetes and Hypertension Onset Education and exercise may determine early start of diabetes and hypertension. Select behavioral and social risk factors were correlated with early onset of hypertension and diabetes, a prospective cohort study found. At 3.5 years of follow-up, among the patients without diabetes at baseline, 4% developed diabetes, while 6.4% of the cohort without baseline hypertension developed hypertension, reported Matthew Pantell, MD, MS, of the University of California, San Francisco, and colleagues.